

Patients	Pat 1	Pat 2	Pat 3	Pat 4	Pat 5	Pat 6	Pat 7	Pat 8	Pat 9	Pat 10	Pat 11	Pat 12	Pat 13	Pat 14	Pat 15
<b>Seizures (0=n/1=y)</b>	1	0	1	0	1	1	1	0	0	0	1	1	1	0	0
...pre-PML (0=n/1=y)	0		0		0	0	0				0	0	0		
...in early PML-phase (pre-IRIS-Phase) (0=n/1=y)	0		1		0	0	0				0	0	0		
...in IRIS-phase (0=n/1=y)	1				1	1	1				1	1	0		
... > 12 months post-PML-diagnosis (0=n/1=y)	1				1		1				0	0	1		
under anticonvulsive therapy (0=n/1=y)	1				1		1						1		
<b>Type of seizures</b>															
focal (0=n/1=y)	1		0		0	1	0				0	0	1		
complex-focal (0=n/1=y)	0		1		0	0	1				0	0	0		
generalized (0=n/1=y)	1		1		1	0	0				1	1	1		
<b>Anticonvulsive therapy</b>															
Levetiracetam (0=n/1=y)	1	1	1	1	1	1	1	0	0	1	1	1	1	1	1
Lamotrigine (0=n/y=1)	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Lacosamide (0=n/1=y)	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
Topiramate (0=n/1=y)	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0
Phenytoin (0=n/1=y)	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0

n=no; y=yes

**Supplemental table 1 – Seizures in PML patients**

Patients	Pat 1	Pat 2	Pat 3	Pat 4	Pat 5	Pat 6	Pat 7	Pat 8	Pat 9	Pat 10	Pat 11	Pat 12	Pat 13	Pat 14	Pat 15
<b>Clinical relapses post-PML</b>															
...(in the year) pre-natalizumab therapy (n)	2	2	2	1	3	2	2	2	3	1	2	2	1	2	2
...under natalizumab therapy (n)	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0
...1-3 months post-PML-diagnosis (n)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
...4-6 months post-PML-diagnosis (n)	0	1		0	0		1	0	0	0	0	0	0	0	0
...7-12 months post-PML-diagnosis (n)	0			0	0		1	0	0	0	0	0	0	0	0
...13-24 months post-PML-diagnosis (n)	0				0		0	0	0	0	0	0	0	0	0
...25-36 months post-PML-diagnosis (n)	0						0	0				1			
...≥37 months post-PML-diagnosis (n)								0							
<b>Paraclinical MS-activity post-PML</b>															
<b>Contrast enhancing MS lesions</b>															
...< 1 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
...1-3 months post-PML-diagnosis (0=n/1=y, 3=no MRI)	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0
...4-6 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0	1		3	3		1	3	0	1	1	0	3	0	3
...7-12 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0			0	3		0	3	3	0	0	3	3	0	1
...13-24 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0				3		0	1	3	0		3	0	1	
...25-36 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0						0	0							
...≥ 37 months post-PML-diagnosis (0=n/1=y/3=no MRI)								1							
<b>Progression of T2-lesions</b>															
...< 1 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
...1-3 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
...4-6 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0	1		3	3		0	3	0	0	0	0	3	0	3
...7-12 months post-PML (0=n/1=y/3=no MRI)	0			0	3		0	3	3	0	0	3	3	0	0
...13-24 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0				3		0	1	3	0		3	0	1	
...25-36 months post-PML-diagnosis (0=n/1=y/3=no MRI)	0						0	0							
...≥ 37 months post-PML-diagnosis (0=n/1=y/3=no MRI)								1							
<b>Time period until first clinical relapse post-PML (in months)</b>	23	4					4					31			
<b>Time period until GD enhancement MS lesions on MRI post-PML (in weeks)</b>		7			3		21	87		17				91	36
<b>Time period until progression of T2-lesions on MRI post-PML (in weeks)</b>		17						87						91	

**Supplemental table 2 – MS activity post-PML**

Patients	Pat 1	Pat 2	Pat 3	Pat 4	Pat 5	Pat 6	Pat 7	Pat 8	Pat 9	Pat 10	Pat 11	Pat 12	Pat 13	Pat 14	Pat 15
Restart of MS therapy post-PML (0=n or not yet/1=y)	1	1	0	1	0	0	1	1	0	1	1	1	0	1	1
Time period until restart of MS therapy post-PML (in months)	5	4		3			16	18		9	9	5		15	9
<b>MS-Therapie post-PML</b>															
Glatiramer acetate (0=n/1=y)	1	0		1			1	0		1	1	1		0	1
Fingolimod (0=n/1=y)	1	0		0			0	0		0	0	0		1	0
Interferonβ-1a (0=n/1=y)	0	1		0			0	0		0	0	0		0	0
Immunglobulines (0=n/1=y)	0	0		0			0	1		0	0	0		0	0

n=no; y=yes

**Supplemental table 3 – MS treatment post PML**